KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Invested Capital (2023 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Return on Invested Capital for 3 consecutive years, with 0.59% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Invested Capital rose 2.0% year-over-year to 0.59%, compared with a TTM value of 0.59% through Dec 2025, up 2.0%, and an annual FY2025 reading of 0.59%, up 4.0% over the prior year.
  • Return on Invested Capital was 0.59% for Q4 2025 at Recursion Pharmaceuticals, up from 0.73% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.58% in Q1 2025 and bottomed at 0.86% in Q1 2024.
  • Average Return on Invested Capital over 3 years is 0.7%, with a median of 0.69% recorded in 2025.
  • Peak annual rise in Return on Invested Capital hit 28bps in 2025, while the deepest fall reached -4bps in 2025.
  • Year by year, Return on Invested Capital stood at 0.77% in 2023, then grew by 21bps to 0.61% in 2024, then grew by 3bps to 0.59% in 2025.
  • Business Quant data shows Return on Invested Capital for RXRX at 0.59% in Q4 2025, 0.73% in Q3 2025, and 0.69% in Q2 2025.